Compare Invesco NASDAQ 100 ETF (QQQM) vs TG Therapeutics Inc (TGTX) Price & Performance

QQQM trades at $309.39, down 0.84% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026 (SEC filing, September 28, 2026).

The outlook remains positive given the Nasdaq-100's exposure to technology growth stocks, though concentration risk in top holdings and potential tax complications with covered-call alternatives like QQQI warrant caution. Market leadership from small-cap stocks within the index suggests continued momentum, but investors should monitor valuation levels given the current price near resistance at $311.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.